The Adult AIDS Clinical Trials Group has responded to research showing a link between HIV antiretroviral treatment and metabolic disorders with guidelines that offer recommendations for assessing, monitoring, and treating the problem. According to the AACTG, up to 40% of HIV patients on a protease inhibitor-containing regimen will have impaired glucose tolerance caused by significant insulin resistance, which can lead to increased risk of cardiovascular complication.